Answers are grounded in this paper and cite their sources.
Biological therapies targeting the interleukin-5 (IL-5) pathway are effective in severe eosinophilic asthma, but treatment responses remain heterogeneous, and reliable predictors of response are lacking. Transcriptomic approaches may help identify molecular signatures associated with clinical outcomes. We conducted a prospective real-world study including 46 patients with severe eosinophilic asthma treated with mepolizumab or benralizumab. Peripheral blood RNA sequencing was performed in a subset of 25 patients at baseline and after 6 months of treatment. Differential gene expression and pathway enrichment analyses were used to characterise shared and treatment-specific transcriptomic effects. Clinical response was assessed using the FEOS score, including identification of super-responders. Both biologics induced significant clinical improvements, including reductions in exacerbations and oral corticosteroid use, as well as improved asthma control and lung function. Transcriptomic analyses revealed a shared molecular signature characterised by downregulation of type 2 inflammatory pathways. Benralizumab was associated with deeper suppression of eosinophil-related transcripts. Benralizumab-specific differentially expressed genes (DEGs), which were predominantly downregulated, were enriched in PI3K/AKT and receptor tyrosine kinase signalling pathways. In contrast, mepolizumab-specific DEGs, also predominantly downregulated, were enriched in immune-regulatory and apoptosis-related pathways. PTGDR2 expression was validated by qPCR and showed significant treatment-associated downregulation. Baseline PTGDR2 expression was associated with super-response and outperformed conventional biomarkers. IL-5 neutralisation and IL-5 receptor blockade induced broadly shared but distinct transcriptomic programs in severe eosinophilic asthma. PTGDR2 may represent a candidate biomarker associated with treatment response. These findings provide mechanistic insights and suggest potential applications for biomarker-guided patient stratification.
No takes yet. Share an insight, caveat, or question.
Estravís et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: